

Global Market Analysis of G-CSF: Trends and Forecasts 2024-2033

The Business Research Company has updated its global market reports with latest data for 2024 and projections up to 2033

LONDON, GREATER LONDON , UK, June 17, 2024 /EINPresswire.com/ -- The G-CSF (granulocyte colony stimulating factors) market size has seen steady growth in recent years, from \$8.84 billion in 2023 to \$9.17 billion in 2024,

at a compound annual growth rate (CAGR) of 3.8%. It will grow to \$10.98 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. This growth can be attributed to the increasing prevalence of cancer, strong economic growth in emerging markets, and higher healthcare expenditures globally.



The Business
Research Company

G-CSF (Granulocyte Colony Stimulating Factors)
Global Market Report 2024 – Market Size, Trends,
And Global Forecast 2024-2033



The Business Research Company has updated its global market reports with latest data for 2024 and projections up to 2033”

*The Business Research
Company*

Increasing Prevalence of Cancer Drives Market Growth
The primary driver of the G-CSF (granulocyte colony stimulating factors) market is the rising prevalence of cancer worldwide. Cancer remains a leading cause of mortality, with significant numbers projected in countries like the United States. For instance, the American Cancer Society estimates approximately 1,958,310 new cancer cases and 609,820 cancer-related deaths in the US alone for 2023. G-CSF plays a crucial role in supporting cancer

patients undergoing chemotherapy by stimulating white blood cell production, thereby reducing the risk of infections and improving recovery rates.

Explore the global G-CSF market with a detailed sample report:

https://www.thebusinessresearchcompany.com/sample_request?id=3466&type=smp

[G-CSF \(Granulocyte Colony Stimulating Factors\) Market Key Players](#) and Market Trends

Major companies such as Amgen Inc., Coherus Biosciences Inc., Sandoz, and Biocon/Mylan are actively involved in the G-CSF market. These companies focus on innovative drug developments,

biosimilar productions, and strategic partnerships to enhance their market presence. For instance, Kyowa Kirin Co. Ltd. launched G-Lasta Subcutaneous Injection 3.6 mg BodyPod, an automated injection device aimed at improving patient convenience and treatment outcomes.

[G-CSF \(Granulocyte Colony Stimulating Factors\) Market Segments](#)

- Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types
- Product: Tablet, Capsule, Other Products
- Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications

Regional Insights: North America Leading the Market

North America emerged as the largest region in the G-CSF market in 2023, driven by advanced healthcare infrastructure, high healthcare expenditure, and a significant patient pool. The report provides detailed insights into regional dynamics and growth opportunities.

Access the complete report for an in-depth analysis of the global G-CSF market:

<https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report>

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2024 from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2024 by [The Business Research Company](#) is the most comprehensive report that provides insights on G-CSF (granulocyte colony stimulating factors) market size, G-CSF (granulocyte colony stimulating factors) market drivers and trends, G-CSF (granulocyte colony stimulating factors) market major players, competitors' revenues, market positioning, and market growth across geographies. The G-CSF (granulocyte colony stimulating factors) market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Protein Expression Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/protein-expression-global-market-report>

Hematology Analyzers And Reagents Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/hematology-analyzers-and-reagents->

[global-market-report](#)

Therapeutic Proteins Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report>

About The Business Research Company

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Twitter: https://twitter.com/tbrc_info

Facebook: <https://www.facebook.com/TheBusinessResearchCompany>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: <https://blog.tbrc.info/>

Healthcare Blog: <https://healthcareresearchreports.com/>

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/720611377>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.